SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (394)4/4/2003 5:54:05 AM
From: scaram(o)uche   of 631
 
There's a post around here somewhere, maybe in the VDXX thread?? Ironic, and adding to the irony..... in 1986 (maybe early 1987), I took Patrick Trown, Vice President, Product Development at XOMA to meet with Mike Gallatin, then of Univ. Washington (Hutchinson) and now V.P./Scientific Director at ICOS. Dr. Gallatin was collaborating with Tommy St. John, now the ICOS V.P., Therapeutics. We discussed Dr. Gallatin's interests in lymphocyte adhesion molecules. Almost 20 years later, by a very circuitous route, anti-CD11a is not only XOMA's life jacket, but Gallatin and St. John could be rolling around to kick them in the backside?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News